A Phase 3 Clinical Trial With ISIS-TTRRx, a 2nd-Generation Antisense Oligonucleotide Targeting Transthyretin (TTR), for the Treatment of TTR Amyloid Cardiomyopathy
Orphanet Journal of Rare Diseases - United Kingdom
doi 10.1186/1750-1172-10-s1-p8
Full Text
Open PDFAbstract
Available in full text
Date
January 1, 2015
Authors
Publisher
Springer Science and Business Media LLC